CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 100 enrolled
Drug / intervention
Placebo Administration +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03927885
NCT03927885Phase 3Active
CompareCT.gov

Open Labeled Placebo for Treatment of Cancer Related Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center·interventional·Posted Apr 25, 2019·Updated Feb 19, 2026

In Brief

A Phase 3 clinical trial evaluating Placebo Administration, Quality-of-Life Assessment, and 2 other interventions for Advanced Malignant Solid Neoplasm and 2 related conditions. Active but no longer recruiting, targeting 100 participants across 1 site.

Detailed Summary

This phase II/III trial studies an open labeled placebo to see how well it works compared with waitlist control in reducing cancer related fatigue in patients with cancer that has spread to other places in the body. A placebo is not a drug and is not designed to treat any disease or illness. Recent studies have found that cancer related fatigue symptoms in cancer survivors are improved with open labeled placebo (that is, patients know they are taking a placebo). It is not yet known how well an open labeled placebo works when compared with waitlist control in reducing cancer related fatigue.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3Active
20202021202220232024202520262027
First PostedApr 25, 2019
Enrollment StartMar 30, 2019
Primary CompletionDec 31, 2026
TodayJul 1, 2026
Enrollment to primary: 7.8 yearsPosted 7.2 years agoPrimary completion in 6 months

Interventions

Placebo Administrationother

Given open labeled placebo PO

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies

Waiting Listother

Assigned to a waiting list